Avidity Biosciences, Inc.
RNA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12,475 | $3,847 | $1,573 | $2,973 |
| % Growth | 224.3% | 144.6% | -47.1% | – |
| Cost of Goods Sold | $0 | $138,125 | $0 | $0 |
| Gross Profit | $12,475 | -$134,278 | $1,573 | $2,973 |
| % Margin | 100% | -3,490.5% | 100% | 100% |
| R&D Expenses | $154,948 | $138,125 | $99,490 | $95,625 |
| G&A Expenses | $46,333 | $36,864 | $33,600 | $28,338 |
| SG&A Expenses | $46,333 | $36,864 | $33,600 | $28,338 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$138,125 | $0 | $0 |
| Operating Expenses | $201,281 | $36,864 | $133,090 | $123,963 |
| Operating Income | -$188,806 | -$171,142 | -$131,517 | -$120,990 |
| % Margin | -1,513.5% | -4,448.7% | -8,360.9% | -4,069.6% |
| Other Income/Exp. Net | $14,364 | $13,827 | $15,744 | $18,733 |
| Pre-Tax Income | -$174,442 | -$157,315 | -$115,773 | -$102,257 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$174,442 | -$157,315 | -$115,773 | -$102,257 |
| % Margin | -1,398.3% | -4,089.3% | -7,360% | -3,439.5% |
| EPS | -1.27 | -1.21 | -0.9 | -0.8 |
| % Growth | -5% | -34.4% | -12.5% | – |
| EPS Diluted | -1.27 | -1.21 | -0.9 | -0.8 |
| Weighted Avg Shares Out | 137,895 | 129,622 | 129,232 | 128,497 |
| Weighted Avg Shares Out Dil | 137,895 | 129,622 | 129,232 | 128,497 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,744 | $14,478 | $16,179 | $18,532 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,056 | $814 | $785 | $738 |
| EBITDA | -$173,386 | -$170,328 | -$130,732 | -$120,252 |
| % Margin | -1,389.9% | -4,427.6% | -8,311% | -4,044.8% |